1. The Modified eCura System for Identifying High-Risk Lymph Node Metastasis in Patients with Early Gastric Cancer Resected by Endoscopic Submucosal Dissection
- Author
-
Kazuhiro Nagao, Masahide Ebi, Takaya Shimura, Tomonori Yamada, Yoshikazu Hirata, Tomohiro Iwai, Takanori Ozeki, Wataru Ohashi, Tomoya Sugiyama, Yoshiharu Yamaguchi, Kazunori Adachi, Shinya Izawa, Yasushi Funaki, Naotaka Ogasawara, Makoto Sasaki, Hiromi Kataoka, and Kunio Kasugai
- Subjects
gastric cancer ,endoscopic submucosal dissection ,risk factor ,lymph node ,metastasis ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background: Endoscopic submucosal dissection (ESD) is widely used for early gastric cancer (EGC) in patients without lymph node metastasis (LNM). Prediction of LNM after ESD is important to determine prognosis in patients with EGC. In this regard, the eCura system was applied to predict LNM after noncurative ESD for EGC. This study aimed to identify risk factors for LNM and improve the accuracy of the eCura system for predicting the risk of LNM after ESD. Methods: A total of 150 patients who underwent noncurative resection of EGC by ESD were retrospectively enrolled at five institutions in Japan. All patients underwent additional surgery with lymph node resection after ESD. The risk factors for LNM among clinicopathological parameters were examined and receiver operating characteristic curve (ROC) analysis was used to determine the optimal cutoff point for predicting high LNM risk using the modified eCura system. Results: Of 150 patients, 19 (13%) had LNM. In the multivariate analysis, lymphatic invasion, and tumor size >30 mm were independent risk factors for LNM. Using a cutoff score of ≥4 for predicting high risk based on the eCura system, the rate of LNM was significantly higher in the high-risk group (4–7 points) than in the low-risk group (0–3 points) (odds ratio 12.0, 95% confidence interval 3.7–54.2, p < 0.0001). Conclusions: An eCura score ≥4 may improve the prediction of LNM risk after ESD in patients with EGC in the intermediate-risk group (2–4 points) of the eCura system, suggesting better treatment strategies for patients. Further prospective and long-term follow-up studies are needed to validate the efficacy of the modified system.
- Published
- 2022
- Full Text
- View/download PDF